{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:39:08Z","timestamp":1787881148376,"version":"build-2784847793"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Polish Ministry of Science and Higher Education","award":["N N405 378437"],"award-info":[{"award-number":["N N405 378437"]}]},{"DOI":"10.13039\/501100007047","name":"Polish-Norwegian Research Fund","doi-asserted-by":"crossref","award":["PNRF\u2013103\u2013AI-1\/07"],"award-info":[{"award-number":["PNRF\u2013103\u2013AI-1\/07"]}],"id":[{"id":"10.13039\/501100007047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.ejmech.2012.11.042","type":"journal-article","created":{"date-parts":[[2012,12,6]],"date-time":"2012-12-06T00:26:27Z","timestamp":1354753587000},"page":"42-50","source":"Crossref","is-referenced-by-count":105,"special_numbering":"C","title":["Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT1A\/5-HT2A\/5-HT7 and dopamine D2\/D3 receptors"],"prefix":"10.1016","volume":"60","author":[{"given":"Pawe\u0142","family":"Zajdel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Marciniec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Ma\u015blankiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Grychowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Sata\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Duszy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Lenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Siwek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Partyka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmara","family":"Wr\u00f3bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Jastrz\u0119bska-Wi\u0119sek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej J.","family":"Bojarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Weso\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Paw\u0142owski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2012.11.042_bib1","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2012.11.042_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbr.2010.01.022","article-title":"The 5-HT7 receptor as a mediator and modulator of antidepressant-like behavior","volume":"209","author":"Sarkisyan","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2012.11.042_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1021\/jm800689g","article-title":"Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior","volume":"52","author":"Butini","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2012.11.042_bib4","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.bmc.2011.12.039","article-title":"Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor\u20135-HT1A\/5-HT2A\/5-HT7 and D2\/D3\/D4\u2013agents: the synthesis and pharmacological evaluation","volume":"20","author":"Zajdel","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2012.11.042_bib5","doi-asserted-by":"crossref","first-page":"6750","DOI":"10.1016\/j.bmc.2011.09.044","article-title":"Arene- and quinoline-sulfonamides as novel 5-HT7 receptor ligands","volume":"19","author":"Zajdel","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2012.11.042_bib6","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.3987\/COM-07-11088","article-title":"From haloquinolines and halopyridines to quinoline- and pyridinesulfonyl chlorides and sulfonamides","volume":"71","author":"Marciniec","year":"2007","journal-title":"Heterocycles"},{"key":"10.1016\/j.ejmech.2012.11.042_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0922-4106(94)90212-7","article-title":"Characterization of the human dopamine D3 receptor expressed in transfected cell lines","volume":"266","author":"MacKenzie","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2012.11.042_bib8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1476-5381.2009.00249.x","article-title":"5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception","volume":"158","author":"Martel","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2012.11.042_bib9","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0022-3565(24)37821-8","article-title":"Functional characterization of the recombinant human 5-hydroxytryptamine7(a) receptor isoform coupled to adenylate cyclase stimulation","volume":"287","author":"Adham","year":"1998","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2012.11.042_bib10","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0091-3057(90)90098-3","article-title":"Do functional relationships exist between 5-HT1A and 5-HT2 receptors?","volume":"36","author":"Darmani","year":"1990","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejmech.2012.11.042_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0014-2999(79)90366-2","article-title":"Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity","volume":"57","author":"Porsolt","year":"1979","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2012.11.042_bib12","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/S0960-894X(03)00389-5","article-title":"N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists","volume":"13","author":"Newman","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2012.11.042_bib13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bmcl.2005.09.053","article-title":"Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility","volume":"16","author":"Chen","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2012.11.042_bib14","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2012.11.042_bib15","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s12325-008-0102-2","article-title":"Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics","volume":"25","author":"Sumiyoshi","year":"2008","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejmech.2012.11.042_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00213-010-2097-z","article-title":"The role of serotonin receptor subtypes in treating depression: a review of animal studies","volume":"213","author":"Carr","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejmech.2012.11.042_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00213-009-1583-7","article-title":"Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice","volume":"206","author":"Bourin","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejmech.2012.11.042_bib18","first-page":"819","article-title":"Maintenance treatment study designs in bipolar disorder: do they demonstrate that atypical neuroleptics (antipsychotics) are moods stabilizers?","volume":"25","author":"Goodwin","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2012.11.042_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1345\/aph.1P397","article-title":"Use of risperidone as augmentation treatment for major depressive disorder","volume":"45","author":"Owenby","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2012.11.042_bib20","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1517\/13543784.2010.515586","article-title":"Quetiapine: novel uses in the treatment of depressive and anxiety disorders","volume":"19","author":"Ravindran","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejmech.2012.11.042_bib21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0166-2236(90)90108-M","article-title":"Systems within the basal ganglia: implications for schizophrenia and Parkinson's disease","volume":"13","author":"Carlsson","year":"1990","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejmech.2012.11.042_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","article-title":"The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia","volume":"20","author":"Jentsch","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejmech.2012.11.042_bib23","first-page":"289","article-title":"Structure-activity relationship studies of CNS agents. Part 9: 5-HT1A and 5-HT2 receptor affinity of some 2- and 3-substituted 1,2,3,4-tetrahydro-beta-carbolines","volume":"48","author":"Bojarski","year":"1993","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejmech.2012.11.042_bib24","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1016\/j.bmc.2007.07.029","article-title":"The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in\u00a0vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines","volume":"15","author":"Paluchowska","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2012.11.042_bib25","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2012.11.042_bib26","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0022-3565(24)37161-7","article-title":"Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites","volume":"283","author":"Owens","year":"1997","journal-title":"J.\u00a0Pharmacol. Exp. Ther."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523412007192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523412007192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T10:31:56Z","timestamp":1745404316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523412007192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":26,"alternative-id":["S0223523412007192"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2012.11.042","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}